Glivin Tablet 400 mg (Imatinib Mesylate)

Adult dose

For adults with chronic myeloid leukemia (CML), a dose of 400mg once daily is recommended for Philadelphia chromosome-positive chronic-phase disease, and 600mg once daily for accelerated- or blast-phase disease. For adults with gastrointestinal stromal tumors (GIST), a dose of 400mg per day is recommended. The recommended dose is 400mg per day for myelodysplastic/myeloproliferative diseases; for hypereosinophilic syndrome/chronic eosinophilic leukemia, the dose may be increased from 100mg to 400mg per day. For recurrent or metastatic dermatofibrosarcoma protuberans, take 800mg per day (400mg twice daily). Take the dose with food. Take 400mg or 600mg once daily, and 800mg twice daily. Patients who have difficulty swallowing the film-coated tablets may take them suspended in water or apple juice.

Child dose

For pediatric patients with chronic myeloid leukemia, a dose of 340mg/m2 per day based on body surface area is recommended. The total daily dose should not exceed 600mg and may be given once daily or divided into 2 doses, in the morning and evening. Pediatric patients may take the dose once daily or in 2 divided doses. For dosage adjustment, the pediatric dose may be reduced from 340mg/m2 to 260mg/m2 or 200mg/m2.

This medication should not be used in patients with known allergies to specific components. Women who are pregnant or may become pregnant should refrain from taking this medication. Women who are breastfeeding should also avoid this medication. It should be used cautiously in patients with impaired liver or kidney function, who require close monitoring by a physician. Patients with a history of heart disease, heart failure, or kidney failure require special attention during treatment, and should seek immediate treatment if symptoms arise. In patients with hypereosinophilia syndrome who have heart infiltration, there is a risk of cardiac shock or left ventricular dysfunction during initial administration, necessitating caution. Patients who have undergone thyroid surgery should regularly check their levels of thyroid-stimulating hormone, as they may experience hypothyroidism. In pediatric patients prior to puberty, growth retardation has been reported, and growth status should be regularly monitored during long-term use. Tumor lysis syndrome may occur, so appropriate treatment for dehydration and high uric acid levels should be addressed before administration. Patients who are carriers of hepatitis B must undergo viral testing prior to this medication and closely monitor their liver condition during and after treatment. While taking this medication, various side effects such as decreased blood cell counts, indigestion, swelling, headaches, nausea, vomiting, muscle pain, diarrhea, rashes, and fatigue may occur, hence symptoms should be discussed with healthcare professionals. Depending on the severity of side effects, dosage adjustment or discontinuation may be necessary. This medication carries risks of serious hepatic toxicity, renal failure, hypophosphatemia, serious respiratory adverse reactions, and tumor lysis syndrome; therefore, regular monitoring is important.

• Neutropenia
• thrombocytopenia
• anemia
• headache
• dyspepsia
• edema
• weight gain
• nausea
• vomiting
• muscle cramps

Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 to 30 degrees Celsius to ensure the efficacy of the medication.

Appearance

Dark yellow-brown oval film-coated tablet

Package unit

30 tablets/PTP